ATE263237T1 - Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung - Google Patents
Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendungInfo
- Publication number
- ATE263237T1 ATE263237T1 AT99201866T AT99201866T ATE263237T1 AT E263237 T1 ATE263237 T1 AT E263237T1 AT 99201866 T AT99201866 T AT 99201866T AT 99201866 T AT99201866 T AT 99201866T AT E263237 T1 ATE263237 T1 AT E263237T1
- Authority
- AT
- Austria
- Prior art keywords
- libraries
- efficient method
- nucleic acids
- gene functions
- sample nucleic
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/097,239 US6413776B1 (en) | 1998-06-12 | 1998-06-12 | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE263237T1 true ATE263237T1 (de) | 2004-04-15 |
Family
ID=22262382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99201866T ATE263237T1 (de) | 1998-06-12 | 1999-06-11 | Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6413776B1 (de) |
| EP (1) | EP1022335B1 (de) |
| JP (1) | JP3672494B2 (de) |
| AT (1) | ATE263237T1 (de) |
| AU (1) | AU756605B2 (de) |
| CA (1) | CA2301403C (de) |
| DE (1) | DE69916005T2 (de) |
| MX (1) | MXPA00012401A (de) |
| NZ (1) | NZ508995A (de) |
| WO (1) | WO1999064582A2 (de) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766891A (en) * | 1994-12-19 | 1998-06-16 | Sloan-Kettering Institute For Cancer Research | Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase |
| US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
| DE69836092T2 (de) * | 1997-10-24 | 2007-05-10 | Invitrogen Corp., Carlsbad | Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen |
| WO1999051620A1 (en) * | 1998-04-03 | 1999-10-14 | Invitrogen Corporation | Libraries of expressible gene sequences |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| ATE286136T1 (de) | 1998-10-06 | 2005-01-15 | Mark Aaron Emalfarb | Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen |
| JP2002535003A (ja) * | 1999-01-29 | 2002-10-22 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | アポトーシスを誘導するｄｎａ配列の単離方法及び検出システム |
| US6642052B2 (en) * | 1999-02-25 | 2003-11-04 | National Research Council Of Canada | Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| JP2003528589A (ja) * | 1999-12-23 | 2003-09-30 | クサントス バイオメディスン アクチエンゲゼルシャフト | 核酸のスクリーニング方法 |
| WO2001059071A2 (en) | 2000-02-09 | 2001-08-16 | Genvec, Inc. | Methods of preparing and using a viral vector library |
| US7078501B2 (en) | 2000-02-25 | 2006-07-18 | Invitrogen Corporation | Topoisomerase linker-mediated amplification methods |
| US7216113B1 (en) * | 2000-03-24 | 2007-05-08 | Symyx Technologies, Inc. | Remote Execution of Materials Library Designs |
| US7122330B2 (en) | 2000-04-13 | 2006-10-17 | Mark Aaron Emalfarb | High-throughput screening of expressed DNA libraries in filamentous fungi |
| EP1276888A2 (de) * | 2000-04-26 | 2003-01-22 | Crucell Holland B.V. | Adenovirale vektoren ohne knob-domäne im fiber protein, und verwendungen davon |
| US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| US6916632B2 (en) * | 2000-08-21 | 2005-07-12 | Invitrogen Corporation | Methods and reagents for molecular cloning |
| US20090118139A1 (en) * | 2000-11-07 | 2009-05-07 | Caliper Life Sciences, Inc. | Microfluidic method and system for enzyme inhibition activity screening |
| NZ526194A (en) * | 2000-12-08 | 2004-10-29 | Invitrogen Corp | Methods of covalently linking, in one or both strands, two or more double stranded nucleotide sequences using one or more topoisomerases |
| US20060008817A1 (en) * | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
| EP1227157A1 (de) * | 2001-01-19 | 2002-07-31 | Galapagos Genomics B.V. | Swap/Gegenselektion: eine schnelles Klonierungsverfahren |
| DE60235161D1 (de) * | 2001-01-25 | 2010-03-11 | Virxsys Corp | Methoden und zusammensetzungen zur identifikation von gen-funktion |
| WO2002070744A2 (en) * | 2001-03-07 | 2002-09-12 | Galapagos Genomics B.V. | Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds |
| US20040132008A1 (en) * | 2002-04-30 | 2004-07-08 | Doranz Benjamin J | Elucidation of gene function |
| EP1256803A1 (de) | 2001-05-07 | 2002-11-13 | Crucell Holland B.V. | Verfahren zur Identifizierung von antiviralen Verbindungen |
| WO2002103321A2 (en) * | 2001-06-14 | 2002-12-27 | Anadys Pharmaceuticals, Inc. | Methods of screening for ligands of target molecules |
| EP1273667A1 (de) * | 2001-07-04 | 2003-01-08 | Galapagos Genomics N.V. | Hochdurchsatzidentifizierung von Angiogenese Modulatoren |
| BR0211111A (pt) | 2001-07-12 | 2004-06-22 | Univ Massachusetts | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula |
| EP1417306A2 (de) * | 2001-08-10 | 2004-05-12 | Xantos Biomedicine AG | Hochdurchsatz dna-isolierung und -transfektion zur analyse der funktion von genen bzw. genprodukten |
| EP1438402A2 (de) * | 2001-08-22 | 2004-07-21 | Galapagos Genomics N.V. | Durch einen screen mit hohem durchsatz identifizierte modulatoren der knochenhomöostase |
| US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| US20030198627A1 (en) * | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| AU2002363076A1 (en) * | 2001-10-26 | 2003-05-06 | Virtual Arrays, Inc. | Assay systems with adjustable fluid communication |
| US7381375B2 (en) | 2001-10-26 | 2008-06-03 | Millipore Corporation | Assay systems with adjustable fluid communication |
| US20080187949A1 (en) * | 2001-10-26 | 2008-08-07 | Millipore Corporation | Multiplexed assays of cell migration |
| CA2414570A1 (en) * | 2002-01-24 | 2003-04-03 | Ecopia Biosciences Inc. | Method, system, and knowledge repository for identifying a secondary metabolite from a microorganism |
| CN100335630C (zh) * | 2002-06-07 | 2007-09-05 | 索菲昂生物科学有限公司 | 筛选方法 |
| US20040219516A1 (en) * | 2002-07-18 | 2004-11-04 | Invitrogen Corporation | Viral vectors containing recombination sites |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| JP4287633B2 (ja) * | 2002-09-18 | 2009-07-01 | 独立行政法人科学技術振興機構 | オルガネラ局在タンパク質の解析方法と解析材料 |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| EP1553983A2 (de) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | Einstellung für rekombinante adenovirus-basierte impfstoffe |
| US20080207465A1 (en) * | 2002-10-28 | 2008-08-28 | Millipore Corporation | Assay systems with adjustable fluid communication |
| JPWO2004046353A1 (ja) * | 2002-11-21 | 2006-03-16 | ジェノミディア株式会社 | 所望の機能的性質を有する核酸の単離方法およびそのためのキット |
| EP1573012B1 (de) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Rekombinanter virus-basierter malaria impfstoff |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| WO2005001133A2 (en) * | 2003-06-03 | 2005-01-06 | Collateral Therapeutics, Inc. | Compositions and methods for high throughput construction and functional analysis of expression libraries |
| US20050059083A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | High throughput method to identify ligands for cell attachment |
| US20050060100A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | Computer software and algorithms for systems biologically linked to cellular phenotype |
| DE602004027538D1 (de) * | 2003-12-01 | 2010-07-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
| AU2003300239A1 (en) * | 2003-12-29 | 2005-07-21 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| EP1737971B1 (de) | 2004-01-20 | 2017-08-16 | Merus N.V. | Gemische bindender proteine |
| JP2007532905A (ja) * | 2004-04-15 | 2007-11-15 | アライド・バイオテック・インコーポレーテッド | ウイルス感染の検出のための方法と装置 |
| DK1745295T3 (da) | 2004-04-20 | 2011-01-31 | Galapagos Nv | Fremgangsmåder, sammensætninger og forbindelsesanalyser til hæmning af produktionen af amyloid beta-protein |
| GB0410105D0 (en) * | 2004-05-06 | 2004-06-09 | Amersham Biosciences Uk Ltd | Method for characterising compounds |
| US7306923B2 (en) | 2004-06-14 | 2007-12-11 | Galapagos N.V. | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| US7485468B2 (en) | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
| CA2585098C (en) | 2004-10-22 | 2018-12-18 | Revivicor, Inc. | Porcine genomic kappa and lambda light chain sequences |
| EP2505651A3 (de) | 2006-12-10 | 2013-01-09 | Dyadic International, Inc. | Pilzisolate mit reduzierter Proteaseaktivität |
| HRP20140405T1 (hr) | 2007-06-20 | 2014-06-20 | Galapagos N.V. | Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova |
| WO2009033071A2 (en) | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
| CL2009001064A1 (es) | 2008-05-07 | 2009-10-09 | Galapagos Nv | Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide. |
| AU2009290848A1 (en) | 2008-09-11 | 2010-03-18 | Galapagos Nv | Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator |
| DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
| WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| TW201120043A (en) | 2009-11-05 | 2011-06-16 | Galapagos Nv | Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases |
| IN2014CN04742A (de) | 2011-11-28 | 2015-09-18 | Crucell Holland Bv | |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US20170247762A1 (en) | 2014-10-27 | 2017-08-31 | The Board Institute Inc. | Compositions, methods and use of synthetic lethal screening |
| EP3234130B1 (de) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Verfahren zum profiling vom t-zell-rezeptor-repertoire |
| US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
| JP6913032B2 (ja) | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
| EP3336169A1 (de) * | 2016-12-15 | 2018-06-20 | Institut Polytechnique de Grenoble | Robotisches verfahren zum beschichten einer multiwellplatte durch einen mehrschichtigen polyelektrolytfilm |
| EP3574116A1 (de) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids |
| CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2019136169A1 (en) * | 2018-01-04 | 2019-07-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Versatile amplicon single-cell droplet sequencing-based shotgun screening platform to accelerate functional genomics |
| WO2020033842A1 (en) | 2018-08-10 | 2020-02-13 | Regenxbio Inc. | Scalable method for recombinant aav production |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| EP3927723A1 (de) | 2019-02-22 | 2021-12-29 | Life Technologies Corporation | Aufhängungssystem für adeno assozierte virusproduktion |
| AU2020316034A1 (en) | 2019-07-23 | 2022-02-10 | Janssen Biotech, Inc. | Synthetic genetic elements for biomanufacture |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| JP7854946B2 (ja) | 2020-05-26 | 2026-05-07 | ディオニス セラピューティクス インコーポレイテッド | 核酸人工ミニプロテオームライブラリー |
| JP2024501482A (ja) | 2020-12-14 | 2024-01-12 | ビオンテック ユーエス インコーポレイテッド | がん免疫療法のための組織特異的抗原 |
| WO2023076733A1 (en) | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
| WO2024015892A1 (en) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Hla-ii immunopeptidome methods and systems for antigen discovery |
| US12531162B1 (en) * | 2023-05-31 | 2026-01-20 | Northeastern University | Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| US12562256B2 (en) * | 2023-11-07 | 2026-02-24 | New York University | Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4497796A (en) | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
| US4727028A (en) | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5208149A (en) | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
| US4740463A (en) | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
| US5518913A (en) | 1991-10-10 | 1996-05-21 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
| CA2053187A1 (en) | 1991-10-10 | 1993-04-11 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
| US6057427A (en) | 1991-11-20 | 2000-05-02 | Trustees Of Dartmouth College | Antibody to cytokine response gene 2(CR2) polypeptide |
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| EP0673431A1 (de) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses) |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2144040A1 (fr) | 1993-07-13 | 1995-01-26 | Michel Perricaudet | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| FR2707664B1 (fr) | 1993-07-13 | 1995-09-29 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| US5401744A (en) | 1993-10-04 | 1995-03-28 | Bristol-Myers Squibb Company | Useful hemi-hydrate form of a cerebral function enhancing agent |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| EP0784690B1 (de) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
| AU711269B2 (en) | 1994-08-16 | 1999-10-07 | Crucell Holland B.V. | Recombinant vectors derived from adenovirus for use in gene therapy |
| US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| WO1997025446A1 (en) * | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| EP0877752B1 (de) | 1996-01-23 | 2003-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen |
| US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| WO1999032618A1 (en) | 1997-12-19 | 1999-07-01 | Strata Biosciences Incorporated | Non-bacterial cloning in delivery and expression of nucleic acids |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
-
1998
- 1998-06-12 US US09/097,239 patent/US6413776B1/en not_active Expired - Lifetime
-
1999
- 1999-06-11 EP EP99201866A patent/EP1022335B1/de not_active Expired - Lifetime
- 1999-06-11 DE DE69916005T patent/DE69916005T2/de not_active Expired - Lifetime
- 1999-06-11 AT AT99201866T patent/ATE263237T1/de not_active IP Right Cessation
- 1999-06-11 AU AU42947/99A patent/AU756605B2/en not_active Expired
- 1999-06-11 WO PCT/NL1999/000367 patent/WO1999064582A2/en not_active Ceased
- 1999-06-11 NZ NZ508995A patent/NZ508995A/en not_active IP Right Cessation
- 1999-06-11 JP JP2000553572A patent/JP3672494B2/ja not_active Expired - Fee Related
- 1999-06-11 CA CA002301403A patent/CA2301403C/en not_active Expired - Lifetime
- 1999-06-11 MX MXPA00012401A patent/MXPA00012401A/es active IP Right Grant
- 1999-07-21 US US09/358,036 patent/US6340595B1/en not_active Expired - Lifetime
-
2001
- 2001-12-21 US US10/036,949 patent/US7029848B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69916005D1 (de) | 2004-05-06 |
| MXPA00012401A (es) | 2003-07-14 |
| WO1999064582A2 (en) | 1999-12-16 |
| CA2301403A1 (en) | 1999-12-16 |
| AU756605B2 (en) | 2003-01-16 |
| EP1022335B1 (de) | 2004-03-31 |
| NZ508995A (en) | 2003-12-19 |
| US7029848B2 (en) | 2006-04-18 |
| CA2301403C (en) | 2009-01-06 |
| AU4294799A (en) | 1999-12-30 |
| WO1999064582A3 (en) | 2000-04-06 |
| JP2002526031A (ja) | 2002-08-20 |
| US6413776B1 (en) | 2002-07-02 |
| US6340595B1 (en) | 2002-01-22 |
| US20030027170A1 (en) | 2003-02-06 |
| EP1022335A1 (de) | 2000-07-26 |
| DE69916005T2 (de) | 2004-09-09 |
| JP3672494B2 (ja) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69916005D1 (de) | Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung | |
| DE60039037D1 (de) | Methode zur direkten sequenzierung von nukleinsäuren | |
| WO2004083225A3 (fr) | Biopuces a sondes et leurs methodes d’utilisation | |
| ATE118549T1 (de) | Verfahren zur synthese von ribonukleinsäure (rns). | |
| DE68921315D1 (de) | Verfahren zur Herstellung synthetischer Oligonukleotide, die spezifisch an Bestimmungsstellen auf Duplex-DNA-Molekülen binden durch Formen eines kolinearen Triplex, die synthetischen Oligonukleotide und Verfahren zu ihrer Herstellung. | |
| ATE343586T1 (de) | Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung | |
| ATE141956T1 (de) | Verfahren zur vervielfältigung von nukleinsäuresequenzen | |
| DE60127162D1 (de) | Massives Parallelverfahren zur Dekodierung von DNA und RNA | |
| ATE545710T1 (de) | Verfahren zur vervielfältigung von nukleinsäuren | |
| DE69034061D1 (de) | Methode der veränderung der expression von genen bei der transkription und zum nachweis von chemischen substanzen, die wie modulatoren der genexpression wirken | |
| ATE282717T1 (de) | Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank | |
| ATE377074T1 (de) | Methode zur bereitstellung von dna sequenzen | |
| EP1012161A4 (de) | Hochempfindliche polymerasen und ihre verwendungen | |
| EP1480155A3 (de) | Informationsverarbeitungsanlage, Informationsverarbeitungsverfahren, Speichermedium und Programm | |
| AU2003291610A1 (en) | Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage) | |
| WO2000022171A3 (en) | Systems and methods for sequencing by hybridization | |
| ATE278808T1 (de) | Verfahren zur charakterisierung von nukleinsäurefragmenten | |
| ATE211180T1 (de) | Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit | |
| EP1335027A4 (de) | Quantifizierungsverfahren für die genetische modifikation und standardmolekül zur verwendung darin | |
| DE59410068D1 (de) | Verfahren zur spezifischen Klonierung von Nukleinsäuren | |
| ATE144557T1 (de) | Nucleinsäure-proben und verfahren zum nachweis von giardia lamblia | |
| ATE317123T1 (de) | Reaktiver träger zur bestimmung von dna fragmenten | |
| DE50014875D1 (de) | Verfahren zum herstellen eines rekombinanten proteins | |
| WO2000021984A3 (en) | Nucleic acids encoding human cide-b protein and polymorphic markers thereof | |
| PT778347E (pt) | Proteina ligante a atp e acidos nucleicos com propriedade de helicase e de atpase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| EEFA | Change of the company name |